Search

Your search keyword '"Mirri, M"' showing total 4 results
Start Over Author "Mirri, M" Database OAIster
4 results on '"Mirri, M"'

1. Guidelines on prostate carcinoma - AIRO, 2016

Author

Santoni, R, Arcangeli, S, Ingrosso, G, Antognoni, P, Mazzeo, E, D'Angelillo, R, Buglione, M, Borghesi, S, Petitti, T, Orecchia, R, Russi, E, Alitto, A, Alongi, F, Augurio, A, Bellavita, R, Bertoni, F, Bonetta, A, Bruni, A, Cagna, E, Cazzaniga, L, Corvo, R, D'Agostino, G, D'Amico, R, Detti, B, De Renzi, F, Fabrini, M, Fersino, S, Frascino, V, Gambarini, S, Genovesi, D, Grazioli, L, Guarneri, A, Jereczek-Fossa, B, Lancia, A, Livi, L, Magrini, S, Mantini, G, Mignogna, M, Mirri, M, Palumbo, I, Pergolizzi, S, Silvestro, G, Rubino, L, Tagliagambe, A, Tonoli, S, Valdagni, R, Vavassori, V, Vinciguerra, A, Santoni R., Arcangeli S., Ingrosso G., Antognoni P., Mazzeo E., D'angelillo R. M., Buglione M., Borghesi S., Petitti T., Orecchia R., Russi E., Alitto A., Alongi F., Augurio A., Bellavita R., Bertoni F., Bonetta A., Bruni A., Cagna E., Cazzaniga L. F., Corvo R., D'agostino G., D'amico R., Detti B., De Renzi F., Fabrini M. G., Fersino S., Frascino V., Gambarini S., Genovesi D., Grazioli L., Guarneri A., Jereczek-Fossa B. A., Lancia A., Livi L., Magrini S. M., Mantini G., Mignogna M., Mirri M. A., Palumbo I., Pergolizzi S., Silvestro G., Rubino L., Tagliagambe A., Tonoli S., Valdagni R., Vavassori V., Vinciguerra A., Santoni, R, Arcangeli, S, Ingrosso, G, Antognoni, P, Mazzeo, E, D'Angelillo, R, Buglione, M, Borghesi, S, Petitti, T, Orecchia, R, Russi, E, Alitto, A, Alongi, F, Augurio, A, Bellavita, R, Bertoni, F, Bonetta, A, Bruni, A, Cagna, E, Cazzaniga, L, Corvo, R, D'Agostino, G, D'Amico, R, Detti, B, De Renzi, F, Fabrini, M, Fersino, S, Frascino, V, Gambarini, S, Genovesi, D, Grazioli, L, Guarneri, A, Jereczek-Fossa, B, Lancia, A, Livi, L, Magrini, S, Mantini, G, Mignogna, M, Mirri, M, Palumbo, I, Pergolizzi, S, Silvestro, G, Rubino, L, Tagliagambe, A, Tonoli, S, Valdagni, R, Vavassori, V, Vinciguerra, A, Santoni R., Arcangeli S., Ingrosso G., Antognoni P., Mazzeo E., D'angelillo R. M., Buglione M., Borghesi S., Petitti T., Orecchia R., Russi E., Alitto A., Alongi F., Augurio A., Bellavita R., Bertoni F., Bonetta A., Bruni A., Cagna E., Cazzaniga L. F., Corvo R., D'agostino G., D'amico R., Detti B., De Renzi F., Fabrini M. G., Fersino S., Frascino V., Gambarini S., Genovesi D., Grazioli L., Guarneri A., Jereczek-Fossa B. A., Lancia A., Livi L., Magrini S. M., Mantini G., Mignogna M., Mirri M. A., Palumbo I., Pergolizzi S., Silvestro G., Rubino L., Tagliagambe A., Tonoli S., Valdagni R., Vavassori V., and Vinciguerra A.

Published
2016

2. Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists

Author

Furlan, C, Arcangeli, S, Avanzo, M, Mirri, M, Munoz, F, Giudici, S, Perrone, A, Amelio, D, Tornio, L, Draghini, L, Deli, A, Pavanato, G, Giuliano, F, Pontoriero, A, Ciammella, P, Navarria, P, Lannalfi, A, Buglione, M, Guida, C, Cammelli, S, Lorio, V, Cardinali, M, Genovesi, D, Barsacchi, L, Balducci, M, Bagnoli, R, Berti, F, Montesi, G, Pasqualetti, F, Bonome, P, Santoni, R, Doino, D, Schirru, P, Pinzi, V, Borzillo, V, Ferrarese, F, Ferro, M, De Cicco, L, Krengli, M, Scoccianti, S, Donato, V, Mirri, MA, DELI, ANIKO' MARIA, Giuliano, FM, PINZI, VALENTINA, Furlan, C, Arcangeli, S, Avanzo, M, Mirri, M, Munoz, F, Giudici, S, Perrone, A, Amelio, D, Tornio, L, Draghini, L, Deli, A, Pavanato, G, Giuliano, F, Pontoriero, A, Ciammella, P, Navarria, P, Lannalfi, A, Buglione, M, Guida, C, Cammelli, S, Lorio, V, Cardinali, M, Genovesi, D, Barsacchi, L, Balducci, M, Bagnoli, R, Berti, F, Montesi, G, Pasqualetti, F, Bonome, P, Santoni, R, Doino, D, Schirru, P, Pinzi, V, Borzillo, V, Ferrarese, F, Ferro, M, De Cicco, L, Krengli, M, Scoccianti, S, Donato, V, Mirri, MA, DELI, ANIKO' MARIA, Giuliano, FM, and PINZI, VALENTINA

Abstract

Purpose To assess the contribution of Italian radiation oncologists in the current management of recurrent high-grade gliomas (HGG), focusing on a reirradiation (reRT) approach. Methods In 2015, the Reirradiation and the Central Nervous System Study Groups on behalf of the Italian Association of Radiation Oncology (AIRO) proposed a survey. All Italian radiation oncologists were individually invited to complete an online questionnaire regarding their clinical management of recurrent HGG, focusing on a reRT approach. Results A total of 37 of 210 questionnaires were returned (18% of all centers): 16 (43%) from nonacademic hospitals, 14 (38%) from academic hospitals, 5 (13%) from private institutions, and 2 (6%) from hadron therapy centers. The majority of responding centers (59%) treated ≤5 cases per year. Performance status at the time of recurrence, along with a target diameter <5 cm and an interval from primary radiation ≥6 months, were the prevalent predictive factors considered for reRT. Sixty percent of reirradiated patients had already received a salvage therapy, either chemotherapy (40%) or reoperation (20%). The most common approach for reRT was fractionated stereotactic radiotherapy to a mean (photon) dose of 41.6 Gy. Conclusions Although there were wide variations in the clinical practice of reRT across the 37 centers, the core activities were reasonably consistent. These findings provide a basis for encouraging a national collaborative study to develop, implement, and monitor the use of reRT in this challenging clinical setting

Published
2018

3. Perfusion Computed Tomography (PCT) adopting different perfusion metrics: Recurrence of brain metastasis or radiation necrosis?

Author

Vidiri, A, Guerrisi, A, Pinzi, V, Fabi, A, Mirri, M, Pompili, A, Caporale, N, Pace, A, Crecco, M, Marzi, S, Vidiri A., Guerrisi A., Pinzi V., Fabi A., Mirri M. A., Pompili A., Caporale N., Pace A., Crecco M., Marzi S., Vidiri, A, Guerrisi, A, Pinzi, V, Fabi, A, Mirri, M, Pompili, A, Caporale, N, Pace, A, Crecco, M, Marzi, S, Vidiri A., Guerrisi A., Pinzi V., Fabi A., Mirri M. A., Pompili A., Caporale N., Pace A., Crecco M., and Marzi S.

Abstract

Objective: Different perfusion metrics were investigated to determine the accuracy of Perfusion CT (PCT) in differentiating recurrence of brain metastases from radiation necrosis in patients who previously underwent stereotactic radiation therapy (SRT). Patients and Methods: Twenty patients previously treated with SRT underwent PCT examination of the brain. Normalized Cerebral Blood Volume (nCBV) values within the region of interest (ROI) were calculated. Fractional volumes at nCBV values between 1.0 and 2.25, defined as V 1.0-V 2.25, were derived as alternative metrics and compared to the conventional method based on the mean CBV value within the lesion (nCBV mean). The Mann-Whitney test was used to compare the two patient's groups with recurrence and radiation necrosis with respect to the different nCBV metrics. Predictive powers and optimal thresholds for both the nCBV mean and the V 1.0-V 2.25 were evaluated using the Receiver Operating Characteristic Curves. The gold standard was represented either by the histopathological examination or the Magnetic Resonance (MR) imaging follow-up longer than six months. Results and Conclusion: The differences between the patient's group with recurrence and that with radiation necrosis resulted statistically significant for all the metrics, showing the lowest p-value for V 1.75 and V 2. The metrics based on the fractional volumes were found to show higher predictive powers, with the highest value of 0.96 for V 2.0. Quantitative analysis of the CBV map deriving different metrics may potentially improve the diagnostic accuracy of PCT in differentiating brain metastasis recurrence from radiation necrosis. © 2011 Elsevier Ireland Ltd. All rights reserved

Published
2012

4. Hypofractionated Conformal Radiotherapy (HCRT) for primary and metastatic lung cancers with small dimension : efficacy and toxicity

Author

Mirri, M, Arcangeli, G, Benassi, M, D'Angelo, A, Pinzi, V, Caterino, M, Rinaldi, M, Ceribelli, A, Strigari, L, Mirri M. A., Arcangeli G., Benassi M., d'Angelo A., Pinzi V., Caterino M., Rinaldi M., Ceribelli A., Strigari L., Mirri, M, Arcangeli, G, Benassi, M, D'Angelo, A, Pinzi, V, Caterino, M, Rinaldi, M, Ceribelli, A, Strigari, L, Mirri M. A., Arcangeli G., Benassi M., d'Angelo A., Pinzi V., Caterino M., Rinaldi M., Ceribelli A., and Strigari L.

Abstract

PURPOSE: : To report on the clinical outcome of hypofractionated conformal radiotherapy (HCRT) for medically inoperable stage I non-small cell lung carcinoma (NSCLC) or limited pulmonary metastases or = 4 months were considered suitable for analysis. Local response was evaluated with CT imaging 4 months after the end of HCRT and every 3 months thereafter. Local relapse-free survival (LRFS) and overall survival (OS) were calculated with the Kaplan-Meier method. RESULTS: : Local response to the treatment was complete response, partial response, no change, and progressive disease as seen in 29%, 43%, 14%, and 7% of tumors, respectively. LRFS at 1 year and 3 years was 76% and 63%, respectively. Lung toxicities > or = grade 2 were observed in 4/40 patients, but no grade 4. Pericardial effusion occurred in one patient. In stage I NSCLC patients (n = 15) with a median follow-up of 25 months, the 1-year LRFS and OS rates were 88% and 81%, respectively, and the 3-year rates 72% and 61%, respectively. CONCLUSION: : HCRT is an effective and low-toxic treatment for medically inoperable early-stage lung cancers and pulmonary metastases for all clinicians lacking the aid of a dedicated stereotactic system.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results